DR Gandara, J Subramanian, ES Santos, Y Brody… - Clinical Lung Cancer, 2024 - Elsevier
Abstract Purpose Immune Checkpoint Inhibitor (ICI) regimens are approved for first-line
treatment of metastatic nononcogene-driven NSCLC. Guidelines do not differentiate which …